Graphical test of the Weibull assumption. Plot of log(-log(Survival)) vs log(time). When the result is a straight line, survival time is considered to follow a Weibull distribution. (PDF 31 kb
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
Additional file 2: Supplementary Table 1. cfDNA Samples Included in 23This Analysisa. Abbreviations:...
Statistical analysis of overall survival with regard to the detection of CTC and mutant KRAS cfDNA i...
Estimated Survival Curves adjusted by sex and age using Cox regression for CTC and KRAS Mutant model...
Specificity of KRAS mutation assays (G12D, G12R and G12V) determined by ddPCR of KRAS mutant and WT ...
Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral b...
Additional file 8. Figure S5: Prognostic values of ctDNA detection based on clonal and subclonal mut...
Additional file 6. Figure S3: Prognostic values of postsurgical ctDNA detection at 3 months and 6 mo...
Analysis of 120 clinically annotated plasma samples from the Komen Tissue Bank, representing 40 samp...
Additional file 9. Figure S6: ctDNA testing, LDCT scans, and disease-related events of patients duri...
Additional file 5. Figure S2: Mutational profile of plasma samples. Gene mutations detected in tissu...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
Additional file 10. Figure S7: Prognostic value of presurgical ctDNA detection. A). The recurrence-f...
Alu115-qPCR values in plasma from healthy controls and patients with gastric cancer. Horizontal line...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
Additional file 2: Supplementary Table 1. cfDNA Samples Included in 23This Analysisa. Abbreviations:...
Statistical analysis of overall survival with regard to the detection of CTC and mutant KRAS cfDNA i...
Estimated Survival Curves adjusted by sex and age using Cox regression for CTC and KRAS Mutant model...
Specificity of KRAS mutation assays (G12D, G12R and G12V) determined by ddPCR of KRAS mutant and WT ...
Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral b...
Additional file 8. Figure S5: Prognostic values of ctDNA detection based on clonal and subclonal mut...
Additional file 6. Figure S3: Prognostic values of postsurgical ctDNA detection at 3 months and 6 mo...
Analysis of 120 clinically annotated plasma samples from the Komen Tissue Bank, representing 40 samp...
Additional file 9. Figure S6: ctDNA testing, LDCT scans, and disease-related events of patients duri...
Additional file 5. Figure S2: Mutational profile of plasma samples. Gene mutations detected in tissu...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
Additional file 10. Figure S7: Prognostic value of presurgical ctDNA detection. A). The recurrence-f...
Alu115-qPCR values in plasma from healthy controls and patients with gastric cancer. Horizontal line...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
IntroductionPretherapeutic detectable circulating tumor DNA (ctDNA) represents a promising prognosti...
Additional file 2: Supplementary Table 1. cfDNA Samples Included in 23This Analysisa. Abbreviations:...